Pasteur International Cancer Conference 2023
Institut Pasteur, November 23-24, 2023

Thursday, November 23, 2023
Welcoming participants
08.15 am-08.45 am (GMT+1)
Introductory remarks
08.45 am-09.00 am (GMT+1)
Session 1: Plasticity, genetics, epigenetics
09.00 am-11.55 am (GMT+1)
Chairs: Pauline Spéder, Institut Pasteur, France - Romain Levayer, Institut Pasteur, France
09.00 am

Ewing sarcoma, a paradigm for cell reprogramming in cancer

Olivier Delattre
Diversity and plasticity of childhood tumors, Institut Curie, Paris, France
09.25 am

Leukemic Stem Cells

Andreas Trumpp
Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
09.50 am

The Splicing-Associated Network PAK1-CLK-SRRM1 is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Camille Vaganay
IRSL, St Louis Hospital, University of Paris-Cité, INSERM UMR 944, Paris, France
10.05 am

MYC and MAX drive the reactivation of the genome after mitosis

Inma Gonzalez
Epigenomics, Proliferation and Cell Identity, Institut Pasteur, Paris, France
10.20 am

Informal discussion / Coffee break

10.45 am

Innate immune self-DNA sensing and cell fate during genotoxic stress

Christian Zierhut
Genome Stability and Innate Immunity Group, The Institute of Cancer Research, London, United Kingdom
11.10 am

Systematic mapping of suppression mutations enabling survival of DNA repair-deficient cancer cells

Francois Dossin
Genome Integrity, Immunity and Cancer Unit, Institut Pasteur, Paris, France
11.25 am

DNA Replication Licensing Aberrations drive genomic instability and are synthetically lethal with FANCD2 and BRCA2 inactivation

Zoi Lygerou
Department of Gen. Biology, School of Medicine, University of Patras, Rio, Patras, Greece
11.40 am

Exploring Oncogenesis with CRISPR to Discover Novel Therapeutic Targets: the example of ROR2 as a new target for ALK+ ALCL

Erika Brunet
Genome Dynamics in the Immune System, Institut Imagine, Montparnasse, France
Lunch and Posters session I (Group photo)
11.55 am-2.00 pm (GMT+1)
Session 2: Competition, heterogeneity, clonality
2.00 pm-4.15 pm (GMT+1)
Chairs: Christian Zierhut, The Institute of Cancer Research, United Kingdom - Erika Brunet, Institut Imagine, France
2.00 pm

Pro- and anti-oncogenic mutants in normal epithelia

Phil Jones
Epidermal and Oesophageal stem cells, Wellcome Sanger Institute, Hinxton, United Kingdom
2.25 pm

P53 activation terminates the fetal-like regenerative state in colitis and promotes a fate switch towards terminally differentiated colonocytes

Kimberly Hartl
Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany Berlin School of Integrative Oncology, Berlin, Germany
2.40 pm

Intra tumoral heterogeneity in breast cancers promote cancer cell extrusion by mechanical cell competition

Carine Rosse
UMR144, Institut Curie - centre de recherche, Paris, France Université Paris Cité, CNRS, Institut Jacques Monod, Paris, France
2.55 pm

Leveraging cell competition against cancer

Jules Lavalou
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
3.20 pm

Insights into "Mechanical Cell Competition": The Independent Roles of Tissue Growth and Junctional Tension

Léo Valon
CDEH, Institut Pasteur, Paris, France UMR 3738, CNRS, Paris, France
3.35 pm

Evolution of cancer cells: improving the explanatory power of the clonal evolution model

Lucie Laplane
IHSPT & U1287, CNRS (Univ Paris 1 & Gustave Roussy), Paris, France
3.50 pm

Informal discussion / Coffee break

Session 3: Motility, biomechanics/physics - Part I
4.15 pm-6.00 pm (GMT+1)
Chairs: Philippe Bousso, Institut Pasteur, France - Isabelle Le Roux, Paris Brain Institute, France
4.15 pm

Regulation of cell fate and integrity by nuclear mechanotransduction

Sara Wickström
Cell and tissue dynamics, University of Helsinki, Finland / Max Planck Institute for Molecular Biomedicine, Muenster, Germany
4.40 pm

Tissue fluidification in pathophysiology

Giorgio Scita
Mechanisms of Tumor Cell Migration, IFOM, University of Milan, Milan, Italy
5.05 pm

Cancer cell collective migration

Fanny Jaulin
Collective invasion, Institut Gustave Roussy, Villejuif, France
5.30 pm

The Mechanobiology of Microtubules: Understanding How Tumour Cells Survive Confined Spaces

Samantha Stehbens
University of Queensland, St Lucia, Australia
5.45 pm

A tug-of-war between cancer stem cells and the host tissue in an invasive tumour of the central nervous system

Pauline Spéder
Structures and Signals in the Neurogenic Niche, Institut Pasteur, Paris, France
6.00 pm-8.00 pm (GMT+1)
Friday, November 24, 2023
Welcoming participants
08.30 am-08.45 am (GMT+1)
Session 3: Motility, biomechanics/physics - Part II
08.45 am-10.35 am (GMT+1)
Chairs: Erik Sahai, The Francis Crick Institute, United Kingdom - Samantha Stehbens, University of Queensland, Australia
08.45 am

Cancer-associated fibroblasts actively compress cancer cells modulating their drug resistance and invasion

Danijela Vignjevic
Cell migration and invasion, Institut Curie, Paris, France
09.10 am

Intravascular cues shape tumor metastasis

Jacky G Goetz
Tumor biomechanics, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France
09.35 am

The effect of interplay between biophysical matrix properties and remodelling on 3D tumor invasion

Anouk Van Der Net
Bionanoscience, Delft University of Technology, Delft, The Netherlands
09.50 am

Role of vimentin in glioblastoma multiforme gene expression

Elvira Infante
Institut Pasteur, Paris, France
10.05 am

Informal discussion / Coffee break

Session 4: Tumor environment: immune system, nervous system, microbiote - Part I
10.35 am-12.05 pm (GMT+1)
Chairs: Giorgio Scita, Istituto Fondazione di Oncologia Moleculaire, University of Milan, Italy - Elvira Infante, Institut Pasteur, France
10.35 am

Cell migration and stromal fibroblasts sculpt patterns of cancer invasion, evolution, and therapy resistance

Erik Sahai
Tumor cell biology, The Francis Crick Institute, London, United Kingdom
11.00 am

Function-based genomics to combat immunotherapy resistance

Daniel Peeper
Functional oncogenomics and resistance to tumor and immune therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
11.25 am

Decoding mechanisms of tumor immunotherapies in vivo

Philippe Bousso
Dynamics of immune responses, Institut Pasteur, Paris, France
11.50 am

Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma

Isabelle Le Roux
Genetic and development of brain tumors, Paris Brain Institute, Paris Cedex13, France
Lunch and Poster session II
12.05 pm-2.00 pm (GMT+1)
Session 4: Tumor environment: immune system, nervous system, microbiote - Part II
2.00 pm-5.20 pm (GMT+1)
Chairs: Jacky G Goetz, Centre de Recherche en Biomédecine de Strasbourg, France - Danijela Vignjevic, Institut Curie, France
2.00 pm

The dark genome and the immune system

Sebastian Amigorena
Immune responses to cancer, Institut Curie, Paris, France
2.25 pm

Cancer Neuroscience of Glioblastoma and Beyond

Frank Winkler
Experimental neurooncology, University Hospital Heidelberg, Heidelberg, Germany
2.50 pm

Neutrophils’ influences on metastatic initiation

Ilaria Malanchi
The Francis Crick Institute, United Kingdom
3.15 pm

Tunneling nanotubes (TNTs) mediated mitochondria transfer in cancer: A focus on Glioblastoma

Ines Saenz de Santa Maria
Trafic membranaire et pathogenèse, Institut Pasteur, Paris, France
3.30 pm

Informal discussion / Coffee break

4.00 pm

Microbiome control of host Immunity

Yasmine Belkaid
Director NIAID Microbiome program, Co-Director NIH Center for Human Immunology, Chief Metaorganism Immunology Section, Chief Laboratory of Host Immunity and Microbiome, United States
4.25 pm

Melanoma immunotherapy by immune checkpoint blockade activates hematopoietic stem cells and reprograms early hematopoïesis

Pierre Guermonprez
Immunology Department, ''Dendritic cells and adaptive immunity'' unit, Institut Pasteur, Paris, France CNRS UMR3738, ''Developmental Biology and Stem Cells'', Paris, France
4.50 pm

New Insights into the Role of Thrombospondin-1 in Glioblastoma Development

Andreas Bikfalvi
Cancer and vascular biology lab (Team 1, INSERM U1312), University of Bordeaux, Pessac, France
5.05 pm

Depletion of slow-cycling PDGFRa+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis

Selene Di Carlo
Stroma, Inflammation & Tissue Repair Unit, Institut Pasteur, Université Paris Cité, INSERM U1224, Paris, France
Concluding remarks
5.20 pm-5.30 pm (GMT+1)


plateforme dédiée aux manifestations
Tel. : 01 84 17 20 55 / 06 89 19 34 06
E-mail :
La première plateforme Française de gestion de manifestations regroupant la billeterie, la gestion des hébergements, une boutique en ligne, la gestion des surfaces d'exposition et la gestion complète du programme scientifique.
Organisation de Congrès, manifestations, Séminiaires, Colloques